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Arsenic trioxide (As2O3) displays apoptogenic proper-
ties against various types of hematopoietic malignan-
cies. We investigated the e¡ects of As2O3 on the
viability of the cutaneous T cell lymphoma cell lines
HuT-78, SeAx, and Myla, and of peripheral blood
mononuclear cells from patients with SeŁ zary syn-
drome, by using propidium iodide and annexin-V
staining, terminal deoxyuridine triphosphate nick end
labeling (TUNEL), cell cycle analysis, mitochondrial
transmembrane potential (DWm) alterations, cyto-
chrome c release, and detection of processed caspase-3.
We also report in vivo e¡ects of As2O3 in two patients
with cutaneous T cell lymphoma. The results show that
As2O3 induces apoptosis of cutaneous T cell lymphoma
lines and of SeŁ zary cells from patients in a time- and
concentration-dependent manner in vitro, as demon-
strated by annexin-V staining, mitochondrial depolari-
zation, and DNA fragmentation. Ascorbic acid 100 lM
potentiated As2O3-induced SeŁ zary cell death, whereas
interferon-a had no synergistic e¡ect. As2O3-induced
SeŁ zary cell death involves activation of caspase-3, clea-
vage of poly(ADP-ribose)polymerase, and cytochrome
c release, but was only partially inhibited by the pan-
caspase inhibitor Z-VAD.£uoromethylketone. Finally,
As2O3 was administered to two patients with cutaneous
T cell lymphoma, allowing us to obtain a partial re-
sponse in one case, whereas stability was observed in
the second patient. These results demonstrate that
As2O3 synergizes with ascorbic acid to induce SeŁ zary
cell death at clinically achievable concentrations,
through a caspase-partially independent pathway, and
provide a rationale for further in vivo studies addressing
the therapeutic e⁄cacy of As2O3 in cutaneous T cell
lymphoma patients. Key words: arsenic trioxide/SeŁ zary
syndrome/apoptosis/vitamin C/cutaneous T cell lymphoma.
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S
eŁzary syndrome (SS) and mycosis fungoides (MF) are
both epidermotropic cutaneous T cell lymphomas
(CTCL) resulting from the clonal expansion of T cells
showing a pattern of cell surface antigens similar to that
of mature memory helper T cells, exhibiting a CD3þ
CD4þ phenotype (Sterry and Mielke, 1989; Bachelez et al, 1995).
Although SS frequently follows an indolent course, it responds
poorly to classical antineoplastic chemotherapy, and interferon-a
(IFN-a) alone or in association with other immunomodulating
therapies such as photopheresis allows only transient and incom-
plete responses (Diamandidou et al, 1996). Likewise, SS is associated
with severe morbidity and mortality, with a median survival of 3^5 y
(Kim et al, 1995). Thus, new therapeutic alternatives are warranted
for the treatment of disseminated forms of CTCL.
Recently, the antineoplastic properties of arsenic compounds re-
ceived wide interest. In vitro studies showed that arsenic trioxide
(As2O3) induces apoptosis of acute promyelocytic leukemia cell
lines at micromolar concentration (Chen et al, 1996), and these pre-
clinical studies received con¢rmation from controlled clinical trials
showing that treatment with As2O3 led to complete remission in
acute promyelocytic leukemia patients refractory to antineoplastic
chemotherapy and/or all-trans retinoic acid (Soignet et al, 1998).
More recently, studies revealed that apoptosis-inducing properties
of As2O3 were not restricted to acute promyelocytic leukemia, as
the viability of di¡erent types of tumors belonging to the lym-
phoid lineage was shown to be altered in vitro in the presence of
various concentrations of As2O3 (Bazarbachi et al, 1999; Rousselot
et al, 1999; Zhu et al, 1999). Zhu et al (1999) showed that As2O3 in-
duces apoptosis and growth inhibition of cell lines derived from
human B cell and T cell chronic or acute malignancies at clinically
reachable concentrations, i.e., between 1 and 2 mM. Recently, evi-
dence for pro-apoptotic e¡ects of As2O3 against multiple myeloma
cells (Rousselot et al, 1999) and human T lymphotropic retrovirus
type I-associated adult T cell leukemia was provided by in vitro stu-
dies (Bazarbachi et al, 1999). Furthermore, recent evidence that as-
corbic acid enhanced the sensitivity of myeloid and lymphoid
malignant cells to As2O3 in vitro provided a rationale for the phar-
macologic modulation of the sensitivity of tumors to As2O3 (Dai
et al, 1999;Yang et al, 1999; Grad et al, 2001).
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In this study, we addressed in vitro the e¡ects of As2O3 on the
viability of peripheral blood mononuclear cells (PBMC) from
patients with SS and of SeŁ zary cell lines. We also investigated
the mechanisms underlying the pro-apoptotic properties of
As2O3 against SeŁ zary cells, and the antineoplastic synergy of a
combination of As2O3 with ascorbic acid. Finally, we report the
in vivo e¡ects of As2O3 in two patients a¡ected with CTCL.
MATERIALS AND METHODS
Reagents Arsenite (As2O3), clinical grade at 510
3 mol per L, was
provided by the Pharmacie Centrale des HoŒ pitaux (Paris, France), stored
at 41C under inert atmosphere, and used at the working concentration
after extemporaneous dilution in RPMI 1640 (Gibco, Life Technologies,
Inc., Galthersburg, MD). Ascorbic acid was purchased from Roche (Neuilly/
Seine, France). N-acetylcysteine, buthionine sulfoxide, and propidium
iodide (PI) were from Sigma Chemical (St Louis, MO). 3,30 -
dihexyloxacarbocyanine iodide (DiOC6) £uorochrome was from
Molecular Probes (Interchim, Montluc on, France). The monoclonal anti-
Fas/CD95 antibody 7C11 (IgM, Fas agonist) as well as £uorescein
isothiocyanate (FITC) conjugated anti-Fas monoclonal antibody UB2, T
cell receptor (TCR) BV-speci¢c monoclonal antibodies conjugated (or
not) with phycoerythrin, and FITC-conjugated annexin-V were
purchased from Immunotech (Beckman Coulter, Marseille, France).
Antibodies against pro-caspase-3 and poly(ADP-ribose)polymerase
(PARP) (rabbit antibody and mouse IgG1, respectively) used for western
blot were from Santa Cruz Biotechnology (Santa Cruz, CA); the
monoclonal antibodies speci¢c for human Bcl-2 oncoprotein (clone 124)
and b-actin (clone AC-15) were from Dako (Glostrup, Denmark) and
Sigma Chemical, respectively; mouse anticytochrome c monoclonal
antibody (6H2.B4), anti-CD3 and anti-CD4 conjugated with either FITC
or allophycocyanine, and phycoerythrin-conjugated rabbit antibody
speci¢cally recognizing the active cleavage product of caspase-3 were
all purchased from BD Biosciences (Le Pont De Claix, France).
Caspase inhibitors including the broad range inhibitor Z-VAD.
£uoromethylketone (Z-VAD.fmk), the pro-caspase-3 inhibitor AC-IETD-
CHO, the caspase-3 inhibitor AC-DEVD-CHO, and the caspase-9-speci¢c
inhibitor AC-LEHD-CHO were purchased from Bachem (Voisins le
Bretonneux, France) and used from 10 mm to the maximal concentration
of 500 mm. Enhanced chemiluminescence western blotting detection
reagents were from Amersham Life Science (Buckingham, UK).
Cell lines The cell line HuT-78 (SS) was purchased from the European
Collection of Animal Cell Cultures (ECACC, Salisbury, UK) and was
cultured at 5104 cells per ml in RPMI 1640 supplemented with 1%
penicillin/streptomycin, 1 mmol per L L-glutamine, and 10% heat-
inactivated fetal bovine serum (RPMI complete medium) at 371C, 5%
CO2. The cell lines SeAx (SS) and Myla (MF) were a kind gift of
Dr Keld Kaltoft (University of Aarhus, Denmark) and were grown under
the same conditions as HuT-78 cells.
Patients’ samples Patients gave written informed consent after approval
by the local Ethical Committee. The diagnosis of SS was established
according to clinical criteria, i.e., a chronic erythroderma with lym-
phadenopathy, and con¢rmed by morphologic investigations showing
SeŁ zary cells on cytologic examination of a peripheral blood smear, and a
dense, band-like dermal in¢ltrate with epidermotropism in skin biopsies.
Essential characteristics of the study patients are listed in Table I. Patients
selected to enter this study exhibited a peripheral blood SeŁ zary cell absolute
count of 1000 per mm3 or more, and a monoclonal status of the T cell
expansion by VgJg PCR multiplex-based analysis, showing in all cases a
massive monoclonal DNA rearrangement both in the lesional skin and in
PBMC (data not shown). The quantitative evaluation of peripheral blood
tumoral cells was assessed by combining CD4/anti-TCRBV double
immunostaining £ow cytometric analysis of PBMC and the method
based on TCRBV complementary determining region 3 length analysis,
also called the immunoscopy method as described previously (Gorochov
et al, 1995; Bachelez et al, 1998). The results represented in Table I show
that the proportion of tumoral cells represented 19%^97% of peripheral
blood CD4 cells, as a monoclonal pattern of TCRBV rearranged genes
was observed in all three cases by using immunoscopy analysis (data not
shown).
Treatments received by study patients prior to inclusion are indicated in
Table I. Patients 3 and 8 did not receive any treatment before study. PBMC
were harvested, isolated by Ficoll-Hypaque density gradient centrifugation,
and incubated in culture complete medium at 5105 cells per mL ¢nal
concentration. After an overnight resting at 371C in a 5% CO2
humidi¢ed atmosphere, As2O3 was added to the culture medium. PBMC
from healthy donors were used as controls.
Proliferative assays of patients’ PBMC were performed over 72 h in
96-well, round-bottomed tissue culture plates (Becton Dickinson,
BD Biosciences) in the presence of a combination of recombinant
interleukin-2 (IL-2) 4 ng per ml and IL-7 10 ng per ml (R&D Systems,
Abingdon, UK) with or without IL-15 10 ng per ml (Peprotech, London,
UK) as previously described (Foss et al, 1994). 3H-thymidine (1 mCi per
well) was added for the last 18 h of culture.
Flow cytometry For double- or triple-£uorescence analysis, 5105
PBMC were harvested by centrifugation, washed in phosphate-bu¡ered
saline (PBS), and incubated for 30 min at 41C with 1^5 mg each
£uorochrome-conjugated monoclonal antibody. Cells were then washed
with PBS and ¢xed with 1% paraformaldehyde in PBS before analysis by
£ow cytometry. All £ow cytometry analyses were carried out on a
FACSCalibur using CellQuest Software (Becton Dickinson).
Assessment of cell death Freshly isolated PBMC or HuT-78 cells were
incubated in complete RPMI medium in the presence of arsenite used at a
¢nal concentration ranging from 0.1 mm to 10 mm. Cell count and viability
were determined by trypan blue dye exclusion or measured by £ow
cytometry analysis of the size/structure ratio of the cells (forward scatter/
side scatter) or after staining with PI 2.5 mg per mL.
Annexin staining Detection of phosphatidylserine on the outer lea£et
of apoptotic cells was performed by using annexin-V binding and PI
Table I. Essential characteristics of study patients with SS, and peripheral blood cell counts at the time of study
Patient no. Age
TNM
staginga
Previous
treatmentsb Leukocytesc Lymphocytesc CD3c CD3/4c CD3/8c
TCRVbd/percent
of CD4þ cells
Percent of
SeŁ zary cells
1 61 T4N1M0 IFN-a, MTX 7800 1830 1660 1562 100 Vb13.1/91.5% 7%
2 71 T4N2M0 Re-PUVA, IFN-a 4800 510 348 320 16 Vb6.B/NA 19%
3 67 T4N2M0 None 17500 13150 12797 12390 422 Vb2/92% 25%
4 73 T4N2M0 Re-PUVA, Cmp, IFN-a 10100 1520 1360 1289 69 Vb7.1/74% 28%
5 76 T4N1M0 Cmp, MTX 29600 11840 10510 9870 310 Vb18/NA 39%
6 61 T4N0M0 IFN-a, ECPC 11900 6100 5917 5734 244 Vb11/97% 35%
7 60 T4N1M0 IFN-a 11300 2540 2370 2259 103 Vb1/84% 34%
8 78 T4N2M0 None 25700 15320 14840 14770 73 Vb3/94.5% 49%
aAccording to the TNM classi¢cation.
bPUVA, psoralen with ultraviolet A radiation therapy; Re-PUVA, retinoids (acitretin) combined with PUVA; Cmp, chloraminophene; MTX, methotrexate; ECPC,
extracorporeal photochemotherapy; NA, not available.
cExpressed as peripheral blood absolute cell counts per cubic millimeter.
dThe TCRVb segment expressed by tumoral cells was identi¢ed by TCRVb/CD4 double immunostaining £ow cytometric analysis of PBMC in six of eight cases, as
PBMC from patients 2 and 5 did not predominantly immunoreact with any anti-TCRVb monoclonal antibody. Nevertheless, the clonal nature of the expansion was
con¢rmed in all cases by PCR analysis of TCRGVGJ rearranged DNA segments, by Vb-family-speci¢c RT-PCR, and by immunoscopy analysis of expanded TCRVb
families. The latter methods revealed a predominant clonal population belonging toTCRVb6.B and toTCRVb18 families in patient 2 and in patient 5, respectively.
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according to the manufacturer’s instructions (Beckman Coulter). Brie£y,
cells were incubated with FITC-conjugated annexin-V in the presence of
1 mmol per L CaCl2 and 2.5 mg per mL PI in order to counterstain nuclei,
and further screened by £ow cytometry (10,000 events). Apoptosis was es-
timated by the relative amount of FITCþ PI cell populations. Under
these conditions, FITCþ PIþ cells correspond to either secondary necro-
tic or postapoptotic cells.
TUNEL assay The terminal deoxytransferase-mediated deoxyuridine tri-
phosphate (dUTP) nick end-labeling (TUNEL) assay was used to monitor
the extent of DNA fragmentation due to apoptosis. The assay was per-
formed on a suspension of CTCL cells according to the recommendations
of the manufacturer (APO-Direct TM Kit, BD Biosciences). Fluorescein-
conjugated dUTP incorporated in nucleotide polymers was detected and
quanti¢ed using £ow cytometry. Fifteen thousand events per sample were
acquired and analyzed using Cell-Quest software.
Furthermore, in order to obtain histologic localization of apoptotic
events in situ, before and after As2O3 in vivo treatment, an improved TU-
NEL assay (DermaTACS, R&D Systems) was developed on frozen skin
sections to detect DNA fragmentation in situ according to the manufac-
turer’s instructions. In brief, frozen lesional skin biopsies were embedded
in a cutting matrix and stored at 801C. Detection of nuclear fragmenta-
tion was performed on 10 mm cryostat sections by incorporating a bro-
minated nucleotide (bromodeoxyuridine, BrdU) at the sites of DNA
fragmentation using terminal deoxynucleotidyl transferase enzyme. The
incorporated BrdU was detected using a highly speci¢c biotinylated anti-
BrdU antibody in combination with a streptavidinhorseradish peroxidase
conjugate. Labeled cells were visualized withTACs Blue label before counter-
staining with Red counterstain C.
Mitochondrial transmembrane potential The sensitive probe DiOC6 was used
to measure mitochondrial transmembrane potential DCm as described else-
where (Djavaheri-Mergny et al, 2001). Brie£y, 106 cells per ml were incu-
bated in RPMI complete medium with DiOC6 100 nM for 30 min at
371C, and then washed with PBS, resuspended in complete medium con-
taining PI 10 mg per ml, and immediately analyzed by £ow cytometry with
laser excitation at 488 nm.
Measurement of oxidative stress The determination of superoxide
production was assessed by measuring the conversion of hydroethidine
(Molecular Probes) to ethidium as previously described by Konorev et al,
1999. Brie£y, after a 24 or 60 h incubation with As2O3, cells were incubated
with 10 mM hydroethidine for 15 min at 371C in the dark. The superoxide
levels were assessed by £ow cytometry analysis using FACSCalibur. The
hydrogen peroxide production was measured by using the 20,70-dichloro-
dihydro£uorescein (H2DCF) probe (Molecular Probes) as described
previously (Konorev et al, 1999). In this case, H2DCF-DA (5 mM)
was added to the cell cultures during the last hour of the incubation period.
Cell cycle analysis Brie£y, 5105 cells were washed twice with ice-cold
PBS, and then ¢xed in cold ethanol 70% for 1 h at 41C. Cells were then
washed twice in ice-cold PBS, pH 7.5, and incubated for 30 min at 371C in
the dark with 200 U per ml DNAse-free RNase A (Sigma). After
centrifugation, cells were resuspended in 1 ml PBS with 10 mg per ml PI
and stored in the dark on ice until £ow cytometry analysis of the DNA
content within the following hour. PI £uorescence emission (15,000
events) was detected using the Cellquest software (Becton Dickinson) and
the quantitation of cells in the pre-G0/G1 phase was performed with
Mod¢t software (Becton Dickinson). Moreover, cellular proliferation of
the HuT-78 cell line was also assessed by incorporation of BrdU during
the last 4 h of As2O3 treatment according to a previously described
method (Lowe et al, 1993). Brie£y, cells were washed twice in PBS and
¢xed in 70% ethanol for 30 min at 201C, and then centrifuged and
resuspended in 0.2 mg per mL pepsin in 2 N HCl. Cells were further
washed, resuspended in 100 mL of fetal bovine serum containing 5 mL
of an FITC-conjugated anti-BrdU antibody (Boehringer, Mannheim,
Germany), and incubated at room temperature for 30 min. Fluorescence-
activated cell sorter analysis was performed on a FACSCalibur, and the
percentage of cells in each phase of the cell cycle was assessed using the
Mod¢t software (Becton Dickinson).
Western blot analysis Approximately 5106 cells were solubilized for
15 min at 41C in lysis bu¡er (20 mmol per LTrisHCl, pH 7.4; NaCl 50 mM;
0.25% Nonidet P-40; 1% Triton X-100; 10 mM ethylenediamine
tetraacetic acid) supplemented with a protease inhibitor cocktail
(Boehringer). The cell-free supernatants were recovered by centrifugation
at 10,000g for 15 min at 41C. The protein concentration of the extracts was
determined by the Lowry method (Bio-Rad Laboratories Life Science,
Hercules, CA). The samples (30 mg of protein per sample) were loaded
onto a 10% or 12% sodium dodecyl sulfate (SDS) polyacrylamide gel,
subjected to electrophoresis, and transferred to a Hybond nitrocellulose
membrane that was subsequently stained with 0.2% Ponceau red. After
blocking of the membrane with 5% nonfat dry milk in Tris-bu¡ered
saline containing 0.1% Tween-20 (50 mmol per L TrisHCl, pH 7.4;
150 mmol per L NaCl; 0.1% Tween-20) for 1 h at 251C, the blots were
incubated for 2 h at room temperature with the appropriate dilution of
the studied antibody (4 mg per ml for anti-caspase-3, and 1:2000 to detect
both the 116 kDa intact and 85 kDa cleaved forms of PARP; 1:40 for anti-
Bcl-2). After washing, the blots were incubated with antirabbit or
antimouse IgG horseradish peroxidase conjugates (1:2000). Binding of
antibodies was detected by staining by chemiluminescence using the ECL
detection kit (Amersham) and quanti¢ed by densitometry. Comparable
loading of proteins on the gel was veri¢ed by re-probing the blots with
an antibody speci¢c for the housekeeping gene product b-actin.
Processing of pro-caspase-3 was also assessed by £ow cytometry using a
phycoerythrin-conjugated rabbit polyclonal antiactive caspase-3 antibody.
Cells were washed with PBS, ¢xed with 0.5% paraformaldehyde in PBS
for 1 h at 41C, and permeabilized in 1 ml of PBS containing 0.2% Tween
for 15 min at 371C. The cell pellets were then washed twice and
resuspended with 20 mL antiactive caspase-3 antibody for 30 min at 41C.
After two washes, approximately 10,000 events were analyzed by £ow
cytometry (detection wavelength 585 nm).
Confocal microscopy In order to detect cytochrome c release, cells
(50,000 per 100 mL) were centrifuged (Cytospin3, Shandon, Pittsburg, PA)
on Superfrost/Plus glass slides (300 g, 2 min) and ¢xed with 1%
paraformaldehyde for 30 min. They were then permeabilized in PBS/
0.2% Tween for 30 min, blocked with PBS containing bovine serum
albumin (BSA, 2%) during 20 min, and incubated with anticytochrome c
antibody for 1 h at room temperature. Cells were washed twice in PBS/2%
BSA and incubated with a secondary antirabbit FITC-conjugated antibody
for 1 h at room temperature. Finally, the coverglass was washed, mounted
with Vectashield Mounting Medium containing DAPI (40,6 -diamino-2-
phenylindole) £uorochrome (Vector Laboratories Inc., Burlingame, CA),
and examined using a laser confocal microscope argonkrypton (Leica).
Immunohistochemistry The detection of CD3, CD4, CD8, and
TCRBV antigens in frozen sections from lesional skin was achieved
using a sensitive streptavidinbiotin a⁄nity method (UltraTech HRP
StreptavidinBiotin Universal Detection System, Coulter-Immunotech,
Marseille, France). Brie£y, after rehydration, 6 mm cryosections were
incubated for 30 min with a primary antibody that binds to a speci¢c tissue
antigen, and then incubated with a biotinylated secondary polyvalent
antibody for 10 min before incubation with streptavidin-peroxidase reagent
(10 min) and development with a freshly prepared substrate/chromogen
solution (10 min, AEC Chromogen System, Immunotech). Sections were
counterstained with hematoxylin before mounting.
Clinical study In order to evaluate the clinical e⁄cacy/toxicity of As2O3
in patients a¡ected with CTCL, an open trial was initiated after approval
by the Ethics Committee of the HoŒ pital Saint-Louis. Patients should
exhibit resistance to at least two types of antineoplastic drug therapy to be
eligible. Two patients a¡ected with a stage III tumoral form of large T cell
CTCL were included. These cases corresponded to a late evolutive stage of
SS (case 6) and MF (case 9) and were both classi¢ed T4N0M0. Both
patients received several di¡erent therapeutic regimens before entering
the therapeutic trial. Thus, patient 6 received IFN-a, extracorporeal
photopheresis, methotrexate, and two lines of antineoplastic polychemo-
therapy. At the time of inclusion into the clinical trial, the latter patient
showed no evidence of circulating tumor cells after morphologic and
immunostaining analysis of PBMC. Indeed, these data di¡ered from
those provided 18 mo ago for the same patient, i.e., at the time of in vitro
studies, which revealed the presence of a predominant clonal population in
the peripheral blood (Table I). Patient 9 previously received antineoplastic
multiple drug therapy of CHOP type, and showed an early relapse of the
disease after autologous bone marrow transplantation. Both patients
received As2O3 at a dosage of 0.15 mg per kg per d for three cycles of 14
d, separated with 14 d intervals. The clinical response was evaluated on the
basis of the surface of skin lesions, according to measurement of the
product of two perpendicular diameters. In one patient showing multiple
skin lesions, four target lesions were chosen for evaluation, and the
percentage of the body surface area involved by skin lesions was also
assessed.
Statistical analysis All values are presented as mean7SD. The
comparisons of cell lines and PBMC populations among control and
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As2O3-treated groups were assessed with the program Stat View for
Macintosh, using the nonparametricWilcoxon test. A p-value of less than
0.05 was considered as statistically signi¢cant.
RESULTS
E¡ects of As2O3 on CTCL cell proliferation Proliferative
assays of PBMC were carried out in the presence of IL-2 and
IL-7, whereas proliferation of HuT-78 cells was assessed without
addition of cytokines. A 20% growth reduction of the HuT-78
cell line was observed at 72 h in the presence of As2O3 1 mM,
and proliferation was almost completely abolished in the
presence of 5 and 10 mM concentrations (Fig 1). The reduction of
proliferative responses of PBMC from patients with SS exceeded
50% with As2O3 1 mM, and reached 90% at 5 mM. These results
represent the mean of three independent experiments.
E¡ects of As2O3 on cell cycle Cell cycle studies were
performed on HuT-78 and PBMC from patients 1, 4, and 6. The
proportion of HuT-78 cycling cells, measured by BrdU
incorporation during the last 4 h, decreased from 33.9% in
control samples to 28.9% and 22.7% in the presence of As2O3 2 mM
and 5 mM, respectively, and to less than 10% at 10 mM. The
percentage of HuT-78 cells in pre-G1 state was not altered by
As2O3 concentrations under 5 mM, and reached 20% and 71%
in the presence of 5 and 10 mM concentrations, respectively. In
the absence of exogenous IL-2 and IL-7, cycling PBMC from
SS patients were barely detectable. A concentration-dependent
increase in the proportion of hypoploid pre-G1 cells was
observed in all samples, reaching 50% in the presence of As2O3
2 mM (Table II).
As2O3 induces apoptosis of HuT-78, SeAx, and Myla CTCL
lines and of PBMC from patients with SS in vitro Serial
analysis of annexin/PI staining allowed an assessment of the
progression from living cells (annexin/PI) towards apoptotic
stage (annexinþ /PI) and postapoptotic cell death (annexinþ /
PIþ ). The results demonstrate that As2O3 induced con-
centration- and time-dependent cell death of HuT-78 and SeAx
cell lines and of PBMC from patients with SS (Figs 2^4). The
viability of HuT-78 cells was assessed in the presence of
concentrations of As2O3 ranging from 1 to 10 mM. The amount
of apoptotic HuT-78 cells, which was not signi¢cantly altered in
the presence of As2O3 1 and 2 mM, reached 25% after incubation
with As2O3 5 mM for 24 h (Fig 2). The proportion of necro-
tic cells (annexin/PIþ ) remained below 10%. Experiments
performed with SeAx cells revealed a proportion of annexin-
positive cells less than 5%77.4% and 12%79.1% in the
presence of As2O3 2 and 5 mM, respectively (mean7SD, n¼ 3)
(Figs 2, 4). Similar results were obtained using the Myla CTCL
line (Fig 4).
The same set of experiments was performed with PBMC from
SS patients and from healthy donors (Tables II, III, Fig 4).
Results showed that the extent of As2O3-induced cell death
of PBMC from SS patients varied from one case to another,
varying from 12.2%72.1% to 68.1%72.6% of annexin-
positive cells after 60 h of incubation with 2 mM As2O3
concentration, and from 39.9%72.25% to 85.9%76.5% for 5
mM. Data from the concentration-dependent cell death obtained
for one patient (case 6) are illustrated in Fig 2 in parallel with
those of the HuT-78 and SeAx cell lines. The kinetics of As2O3-
induced cell death of PBMC from the same patient are illustrated
in Fig 3. It is noteworthy that, as shown in Fig 4, mean
sensitivities of PBMC from healthy donors and from patients
with SS to As2O3-induced cell death at a 2 mM concentration
were not signi¢cantly di¡erent, whereas a signi¢cantly higher
sensitivity of the former was observed at a 5 mM concentration
(po0.02). Moreover, results from apoptosis assays comparatively
performed with PBMC from patient 5 in the presence and in the
absence of a combination of IL-2 and IL-7, i.e., a combination
known to support in vitro expansion of SeŁ zary cells, showed that
24% of cells were annexin positive versus 53% without addition
of cytokines after 60 h of incubation with As2O3 5 mM (data
Figure1. Concentration-dependent e¡ects of As2O3 on the prolif-
eration of HuT-78 tumor cell line and PBMC from patient 1. HuT-
78 cells were cultured for 72 h in the presence of increasing concentrations
of As2O3 in complete RPMI medium without exogenous cytokines.
PBMC were isolated from patient 1 and seeded at 5105 cells per mL in
RPMI medium with exogenous human recombinant IL-2 (2 ng per mL)
and IL-7 (10 ng per mL). The next day, cells were incubated for 72 h in the
presence of As2O3 in complete RPMI mediumwith addition of exogenous
cytokines. Determination of cell proliferation was assessed by [3H]thymi-
dine uptake (1 mCi per well) during the last 18 h of incubation. Results are
expressed as the percentage of the untreated control (mean7SD, n¼ 6)
(p¼ 0.05 compared to control samples).
Table II. Results from cell cycle analysis of HuT-78 cell line and PBMC from three patients with SS
Pre-G1 (apoptosis) SþG2þM (cycling cells)
Treatment HuT-78 Patient 1 Patient 4 Patient 6 HuT-78
Control 7.170.9 20.572.5 20.473.3 5.371.4 30.972
As2O3 0.1 mM 6.670.2 18.572.2 16.971.7 3.970.6 31.472
As2O3 0.5 mM 8.270.7 NA 20.172.4 8.7571.5 30.272
As2O3 1 mM 8.770.7 30.872.7 31.371.2 29.675.7 27.972.3
As2O3 2 mM 7.970.8 46.672.8 42.4713.1 45.976.9 28.372.6
Doseresponse of As2O3-induced apoptosis was analyzed by DNA £ow cytometry using Mod¢t software.
Sub-G1 fractions at 60 h increased with increase in the As2O3 dosage in both HuT-78 cells and PBMC from SS patients 1, 4, and 6.
Cell cycle analysis of HuT-78 cells incubated or not with As2O3 was assessed by incorporation of BrdU during the last 4 h of incubation.
Results for apoptosis are the mean percentage of sub-G1 cells (mean7SD, n¼ 3).
Results for cycling cells are the mean percentage of BrdU-positive cells (mean7SD, n¼ 3).
NA, not available.
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not shown). Similar results were obtained in the presence of
recombinant IL-15 10 ng per ml (data not shown). Spontaneous
cell mortality remained below 10%.
The apoptotic phenotype was con¢rmed by results from the
TUNEL assay (Fig 5). Indeed, the rate of £uorescently stained
cells among PBMC from SS patients reached 50% in the
presence of 5 mM As2O3 during 60 h (Fig 5). Examination of
TUNEL-stained cells by £uorescence microscopy con¢rmed the
apoptotic nature of the As2O3-induced death process of the HuT-
78 cell line and of patients’ peripheral blood SeŁ zary cells (data not
shown).
E¡ects of As2O3 on mitochondria As2O3-induced apoptosis
of HuT-78 and PBMC from patients with SS is characterized
by an early, concentration-dependent dissipation of the mito-
chondrial transmembrane potential (DCm) (Fig 6). DCm loss in
SS PBMC, however, was obtained with concentrations of As2O3
lower than in experiments with HuT-78. Incubation with 2 mM
As2O3 induced a dissipation of more than 50% in PBMC from
patients with SS, whereas DCm loss was less than 25% in HuT-78
cells (Fig 6A). Moreover, mitochondria involvement in As2O3-
induced apoptosis was con¢rmed by cytochrome c translocation
from mitochondria into the cytoplasm in HuT-78 after As2O3
exposure as assessed by immunocytologic staining and confocal
microscopy analysis (Fig 6B).
Sensitivities of clonally expanded CTCL cells and of
nontumoral T cells to As2O3-induced cell death are within
the same range In order to comparatively assess the sensitivities
of tumoral and nonmalignant lymphocytes to apoptosis induced by
As2O3 in patients with SS, we monitored the percentage of living
tumoral cells among peripheral blood T cells by using double
immunostaining analysis of living cells (PI negative) with anti-
CD3 and anti-TCRBV monoclonal antibodies. The appropriate
anti-TCRBVmonoclonal antibody was selected on the basis of its
immunoreactivity with the TCRBV segment carried by tumoral
cells. Results from analysis performed in three cases showed no
signi¢cant change in the proportion of tumoral cells among
CD3þ PBMC after As2O3 treatment (Fig 7).
The mechanism of As2O3-induced cell death of CTCL
cells is partially independent of caspase activation In order
to dissect the mechanisms of As2O3-induced apoptosis of SeŁ zary
cells, we evaluated the contribution of caspase-3 by using
cyto£uorimetric analysis and western blot. Cyto£uorimetric
analysis of caspase-3 activity revealed activation following
As2O3 treatment (Fig 8A). Western blotting gave con¢rmation
of caspase-3 activation, revealing a speci¢c proteolytic cleavage
of PARP from 116 kDa to 85 kDa (Fig 8B). As a positive
control, the HuT-78 cell line was incubated with the anti-CD95/
Fas 7C11 monoclonal antibody.
Moreover, series of apoptosis assays were carried out in the
presence of caspase inhibitors, and compared with results
obtained in control experiments. The oligopeptide pancaspase
inhibitor Z-VAD.fmk led to a 20% inhibition of As2O3-
induced HuT-78 cell death as measured by annexin staining,
whereas no evidence of inhibition was observed in PBMC from
SS patients following a 1^4 h preincubation in the presence of
high concentrations of Z-VAD.fmk, up to 500 mM (Fig 9).
Accordingly, incubation of HuT-78 or PBMC with other cas-
pase inhibitors did not alter As2O3-induced DCm loss (data not
shown). In contrast, incubation with Z-VAD.fmk completely
Figure 2. Concentration-dependent apoptosis of HuT-78 and SeAx cell lines, and of PBMC from one patient with SS. HuT-78 and SeAx cell
lines (panels A, B, respectively) and PBMC from patient 6 (panels C) were incubated with concentrations of As2O3 ranging from 0.5 mM to 5 mM in complete
RPMI medium (without exogenous cytokine addition) for 60 h. Flow cytometry analysis of cells with annexin-V/PI double staining shows in the lower left
quadrant the double-negative nonapoptotic cells. The lower right quadrant represents the annexinþ /PI^ early apoptotic cells. The upper right quadrant represents
the double-positive late apoptotic cells. The results were representative of at least six comparable experiments.
ARSENIC TRIOXIDE INDUCES APOPTOSIS OF CTCL CELLS 885VOL. 121, NO. 4 OCTOBER 2003
abolished anti-CD95-mediated apoptosis of HuT-78 cells,
depicted either by annexin/PI staining or by DCm analysis.
Of note, a basal expression of the bcl-2 oncoprotein was
detected by western blot and £ow cytometry in all SS
PBMC, and was not altered following treatment with As2O3, as
shown for HuT-78 cells and PBMC from patient 2 and patient 8
(Fig 10).
Ascorbic acid synergizes with As2O3 to promote CTCL cell
death In an attempt to investigate the e¡ects of pharmacologic
agents, which have been shown to potentiate As2O3-induced
apoptosis of malignancies other than CTCL, we performed
apoptosis assays with the HuT-78 cell line and PBMC from SS
patients in the presence of As2O3 with or without ascorbic acid.
The results show that ascorbic acid 100 mM synergizes with
As2O3 to induce apoptosis of SeŁ zary cells (Table III). The
incubation of PBMC from four SS patients with As2O3 2 mM
in association with ascorbic acid led to a decrease in cell viability
ranging from 15% to 50% in comparison with control samples,
and exceeding 70% with As2O3 5 mM (Table III). Notably,
ascorbic acid did not potentiate As2O3-induced death of PBMC
from three healthy donors. Furthermore, IFN-a 100 U per ml
did not potentiate As2O3-induced death of SS PBMC (not
shown).
Results from additional experiments showed that buthionine
sulfoxide, an agent that induces a depletion of intracellular
glutathione (GSH) content, synergizes with As2O3 in inducing
apoptosis of HuT-78 and PBMC from SS patients (Table IV),
whereas N-acetylcysteine, an antioxidant that preserves the GSH
level, inhibited As2O3-induced tumoral cell death (Table IV).
As a relationship between reactive oxygen species (ROS) and
apoptosis of various cellular types has been advocated, we used
the ROS-sensitive £uorogenic dyes 20,70-dichloro£uorescein
diacetate (H2DCF-DA) and dihydroethydium for measurement
of intracellular peroxide and superoxide anion levels, respec-
tively. The generation of ROS was detected by £ow cytometric
analysis of HuT-78 and of PBMC from patients 3 and 8 fol-
lowing a 24 h incubation with As2O3. Again, the production of
ROS was concentration dependent, and was enhanced by
cotreatment with 100 mM ascorbic acid as shown by superoxide
anion detection (data not shown).
Clinical course in two patients with CTCL receiving
As2O3 Patients 6 and 9 were treated with intravenous infusions
of As2O3 0.15 mg per kg per d for 14 consecutive days. Three
cycles were initially planned, each cycle being followed by a 14
d resting interval. Patient 6 developed ulceration of several
nodular lesions, some of which regressed after the ¢rst cycle of
treatment. As other lesions progressed, however, the extent of
cutaneous tumoral involvement was considered as stable. Of
note, this patient, who participated in the in vitro study 6 mo
before the clinical trial (case 6), did not show any peripheral
blood SeŁ zary cells at cytologic examination, nor any clonal re-
arrangement of TCR-g loci. Treatment with As2O3 was stopped
in patient 6 because of the occurrence of encephalopathy, which
completely resolved within 4 wk after treatment withdrawal.
Thereafter, the patient developed disseminated lesions and died
of sepsis. In situ studies of DNA fragmentation by the TUNEL
method, which were performed on a frozen skin biopsy taken at
the end of the ¢rst cycle of As2O3, revealed apoptotic tumoral
cells in both patients (Fig 11). Patient 9 experienced a marked
regression of skin lesions after 14 d of treatment, without
evidence of ulceration (Fig 12). In the latter patient, As2O3 was
withdrawn 4 d after the onset of the second cycle because of
peripheral neural toxicity revealed by dysesthesia. Three weeks
after As2O3 withdrawal, a progression of skin lesions was
evident. In this case, As2O3 dosage was performed in fresh
lesional versus nonlesional skin biopsies taken at the end of the
¢rst cycle of treatment with As2O3, and showed that As2O3
Figure 3. Time-dependent apoptosis of PBMC from one patient
with SS. PBMC from patient 6 were incubated with As2O3 5 mM in
complete RPMI medium. In panels A is shown the side scatter/forward
scatter £ow cytometry analysis, whereas panels B represent results from
annexin-V/PI double staining analysis. Analyses were serially performed
after 12, 24, 36, 60, and 84 h of incubation with As2O3.The lower left quad-
rant represents the double-negative nonapoptotic cells. The lower right
quadrant represents the annexinþ /PI^ early apoptotic cells.The upper right
quadrant represents the double-positive late apoptotic cells. The results
were representative of at least three comparable experiments.
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concentration in lesional skin far exceeded that in nonlesional
skin (121.7 vs 81.8 nmol per g, respectively).
DISCUSSION
We present the ¢rst evidence of death-promoting e¡ects of
As2O3 against CTCL cells. It is noteworthy that CTCL usually
exhibits a remarkable resistance towards antineoplastic drugs
in vivo, and clinical trials in patients with MF/SS have shown that
so far treatment with antineoplastic chemotherapy o¡ered no
bene¢t in terms of mortality (Diamandidou et al, 1996). Further-
more, the use of immunomodulatory regimens such as IFN-a
and/or extracorporeal photochemotherapy o¡ers transient and
partial remission. Thus, new therapeutic agents that are able to
overcome chemoresistance are warranted for the treatment of pa-
tients with disseminated forms of MF/SS. The preferential di¡u-
sion of As2O3 into the skin and its antitumoral e¡ects in vitro
against adult T cell leukemia ^ a T cell malignancy sharing with
SS/MF a CD4þ phenotype ^ o¡er a rationale for the clinical use
of As2O3 in patients with CTCL (Bazarbachi et al, 1999). No evi-
dence of apoptosis-inducing properties of As2O3 on SeŁ zary cells
has been previously provided, however. In this in vitro study, we
focused on the e¡ects of clinically achievable concentrations of
Figure 4. E¡ects of As2O3 on the viability of CTCL HuT-78, SeAx, and Myla cell lines, of PBMC from patients with SS, and of PBMC from
healthy donors. Cell viability was assessed by £ow cytometry analysis of annexin-VFITC/PI staining after a 60 h incubation in the presence of As2O3 2
or 5 mM (plain bars and dotted bars, respectively). Results are expressed as the percentage of viable cells, de¢ned as annexin^/PI^ cells, with cells incubated
with control medium as 100% (mean7SD, n¼ 3).
Table III. E¡ects of ascorbic acid on As2O3-induced cell death
As2O3 Ascorbic acid Patient 1 Patient 3 Patient 5 Patient 7 Patient 8 HuT-78
0 mM 100 mM 94.670.9 93.573.1 92.973 97.470.6 103.274.5 94.770.4
2 mM 0 68.578.6 100.878.6 84.870.3 46.274.5 77.670.1 96.970.8
100 mM 53.376.1 93.570.7 81.176.5 40.472.4 58.372.1 91.471.8
5 mM 0 39.676.6 54.772.3 58.375.3 41.270.2 50.275.1 67.472.6
100 mM 10.870.9 49.972.6 11.670.8 31.271.4 37.379.5 33.275.7
Cell viability was assessed by £ow cytometry analysis after immunostaining with annexinFITC and PI.
Cells were incubated for 60 h with As2O3 in the presence or not of ascorbic acid.
Results are expressed as the mean percentage of viable cells (annexin/IP) with the untreated cells taken as 100% (mean%7SD, n¼ 3).
Figure 5. Flow cytometry analysis of DNA fragmentation (TU-
NEL assay). DNA fragmentation of PBMC from SS patients 1 and 4 after
incubation with increased concentrations of As2O3 for 60 h was deter-
mined by £ow cytometry analysis of dUTPFITC and PI double staining
according to the TUNEL assay (mean percentage7SD, n¼ 3).
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Figure 6. Direct e¡ects of As2O3 on
mitochondrial transmembrane poten-
tial DWm and cytochrome c release.
Potentiation by ascorbic acid. (A) Mito-
chondrial transmembrane potential DCm.
The mitochondrial transmembrane poten-
tial DCm was detected in freshly isolated
PBMC from patient 8 (left panel) and
HuT-78 cells (right panel) by using the sen-
sitive probe DiOC6 at the end of the 60 h
incubation with 2 mM (left) or 5 mM (right)
As2O3 with (shaded lines) or without (dotted
lines) ascorbic acid (100 mM). Green dot
lines represent the mitochondrial trans-
membrane potential DCm in control cells.
These results were representative of at
least six comparable experiments. (B) Cy-
tochrome c release. As2O3 exposure pro-
motes release of cytochrome c from the
mitochondria into the cytoplasm. HuT-78
cells were treated with control medium
(up) or with As2O3 5 mM (down) for either
24 or 60 h. Cells were stained with a spe-
ci¢c cytochrome c antibody revealed by
a secondary FITC-conjugated antibody
(green) and mounted with a DAPI-contain-
ing medium (blue nuclei). They were ana-
lyzed by confocal microscopy.
Figure 7. Analysis of clonally ex-
panded tumoral cells following in vitro
As2O3 treatment of PBMC from three
patients with SS. Upper panel, left: For-
ward/side scatter diagram; R1 is the lym-
phocytic gate. Upper panel, right: Double
staining with CD3 and the speci¢c
TCRBV, carried by the clonal cell popula-
tion (Sezary cells) from patient 1; 81% of
the CD3-positive cells express the speci¢c
TCRBV. Lower panel: Percentage of CD3-
positive cells expressing the speci¢c
TCRBV after 60 h of incubation with ¢ve
dosages of As2O3 (0.1, 0.5, 1, 2, and 5 mM)
for three di¡erent patients; the proportion
of tumoral cells remains stable despite in-
creasing As2O3 concentrations.
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As2O3, which have been shown to range between 1 and 2 mM
(Soignet et al, 1998; Zhu et al, 1999), on the viability of PBMC
from patients with SS, which were selected on the basis of a high
ratio of peripheral blood tumoral cells. Our results indicate that
As2O3 used at a clinically achievable concentration induced apop-
tosis of freshly puri¢ed peripheral blood SeŁ zary cells in vitro,
although the As2O3 concentration required ranged between 2
and 5 mM from one patient to another. Experiments with CTCL
cell lines yielded similar results, supporting the relevance of these
lines for in vitro studies investigating apoptosis induced by mito-
chondrial drugs.We also provide evidence that the sensitivity of
SeŁ zary cells to As2O3-induced cell death is lower than that of T
cells from healthy donors for a 5 mM concentration. These data
are in disagreement with those obtained on adult T cell leukemia
cells by Bazarbachi et al (1999), who reported a higher sensitivity
of PBMC from adult T cell leukemia patients than PBMC from
healthy donors. In the latter study, the lack of assessment of the
respective representations of clonally expanded tumoral T cells
and nontumoral cells before and after treatment with As2O3 pre-
cluded evaluation of the sensitivities of both tumoral and nontu-
moral T cell subsets from a given patient to As2O3-mediated cell
death. Of note, several patients of this study experienced resis-
tance to antineoplastic chemotherapy, to a-INF, and/or to extra-
corporeal photopheresis prior to the study, suggesting that As2O3
might be a candidate drug in order to overcome this chemoresis-
tance in vivo. This biased selection of patients might partly explain
the heterogeneous sensitivity of SS PBMC toAs2O3-induced cell
death observed in our work. On the other hand, several antia-
poptotic factors, including oncoproteins of the bcl-2 family,
might participate in the partial resistance of CTCL cells to
As2O3-induced apoptosis (Dalloul et al, 1992; Dummer et al,
1995; D˛bbeling et al, 1998; Qin et al, 2001).
These results demonstrate that As2O3 induces SeŁ zary cell death
through a pathway that is partially independent of caspases. Cas-
pase-independent cell death of human mature T cells has been
previously reported following activation through CD2 or
exposure to staurosporine (Deas et al, 1998). Our results show
the partial contribution of a caspase-independent pathway in
As2O3-induced CTCL cell death of normal and malignant T
lymphocytes. Although the nature of the molecular mechanisms
leading to caspase-independent cell death have not been fully
elucidated yet, a major role for mitochondrial dysfunction and
for redox imbalance has been advocated (Green and Kroemer,
1998), with subsequent release of mitochondrial proteins such as
cytochrome c (Shimizu et al, 1999), apoptosis-inducing factor
(Susin et al, 1996), and Smac/diablo (Du et al, 2000) into the cyto-
sol. Indeed, our results con¢rm the involvement of cytochrome c
release from mitochondria into the cytoplasm in apoptosis in-
duced by As2O3, as described for other chemotherapeutic agents
(Liu et al, 1996), and it would be of interest to further investigate
the respective contributions of apoptosis-inducing factor and
Smac/diablo to SeŁ zary cell death induced byAs2O3.
The potentiation of As2O3-induced SeŁ zary cell death by ascor-
bic acid on one hand, and the alterations of As2O3-induced apop-
tosis by GSH-content-modulating agents and the increase in
dihydroethydium and in DCFH-DA oxidation to DCF following
treatment with As2O3/ascorbic acid on the other hand, indicate
that ROS and hydrogen peroxide formation modulate As2O3-
induced SeŁ zary cell death. Enhancing properties of ascorbic acid
on As2O3-induced death of B cell malignancies have recently
been demonstrated by in vitro studies addressing B cell lym-
phomas and multiple myeloma cells (Dai et al, 1999; Grad et al,
2001). Furthermore, ROS have been shown to regulate in vivo
the death of nonmalignant peripheral T lymphocytes following
Figure 8. E¡ects of As2O3 on caspase-3 ac-
tivity. (A) Cyto£uorimetric analysis of cas-
pase-3 activity was determined in tumoral
PBMC from patient 8 after a 60 h As2O3 incu-
bation. Intracytoplasmic active caspase-3 was
detected by a phycoerythrin-conjugated antic-
aspase-3 antibody in tumoral CD4-positive
cells. Dotted lines represent caspase-3 activity
depicted in untreated control cells. (B)Western
blot analysis of caspase-3 and PARP in HuT-78
cells after incubation with As2O3 for 60 h or
with 0.1 mg per mL 7C11 (Fas agonist) for 24
h. A decrease in pro-caspase-3 (32 kDa) is ob-
served in the presence of As2O3 concentrations
of 5 and 10 mM (upper panel). A cleavage of
PARP (116 kDa to 85 kDa) is also detected at
the same concentrations (lower panel).
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proapoptotic stimuli other than As2O3 such as antigenic and
superantigenic activation (Castedo et al, 1995; Hildeman et al,
1999). Thus, although the mechanisms underlying this synergy
between ascorbic acid and As2O3 remain unclear, it appears that
the balance between the GSH content and the production of
ROS is a key factor determining apoptosis of SeŁ zary cells.
Furthermore, our results and those recently obtained with acute
promyelocytic leukemia and B cell lymphoma cell lines indicate
that ROS and lipid peroxidation regulate cell death of various
types of hematopoietic malignancies ( Jing et al, 1999). Besides an
increased production of H2O2, the low sensitivity of SeŁ zary cells
to As2O3-induced apoptosis might also depend on the activity of
H2O2 scavenging enzymes including glutathione peroxidase and
catalase, which have been shown to be upregulated in human leu-
kemia cell lines (Jing et al, 1999). In our study, we did not ¢nd
evidence of any synergy between IFN-a and As2O3 in SeŁ zary cell
death induction. These results di¡er from those reported by stu-
dies on adult T cell leukemia, which showed that pro-apoptotic
synergistic e¡ects of the As2O3IFN-a combination were related
at least partly to a downregulation of the Tax oncogenic protein,
and to an inactivation of the nuclear factor kB (NF-kB) pathway
(Bazarbachi et al, 1999; El-Sabban et al, 2000). Interestingly, consti-
tutive activation of NF-kB has been reported in HuT-78 cells and
Figure 9. E¡ects of caspase inhibitors on As2O3-induced apoptosis in HuT-78 cells and PBMC from one patient with SS.The e¡ects of caspase
inhibitors (ZVAD, DEVD, IETD, LEHD) were studied on cell viablity (annexin/PI cells) and DCm collapse (intact and high DiOC6 staining) in HuT-
78 cells and PBMC from patient 8 incubated with As2O3 for 24 h. Results are the mean of triplicate samples with standard deviation less than 5%. Control
cells without As2O3 and caspase inhibitors are taken as 100% for annexin and DiOC6 staining percentage.
Figure10. As2O3 treatment does not alter Bcl-2 expression in the
HuT-78 cell line and PBMC from patients with SS. HuT-78 cells and
PBMC isolated from patients with SS (patient 2 and patient 8) were cul-
tured in the presence of As2O3 2, 5, and 10 mM for 60 h.Whole-cell extracts
were prepared and analyzed by immunoblotting for Bcl-2 expression
(mouse monoclonal IgG1k 1:40, secondary antibody 1:2000). Thirty-¢ve
micrograms, 8.85 mg, and 11.4 mg proteins, respectively, extracted from
HuT-78, PBMC from patient 2, and PBMC from patient 8, were loaded
on 10% SDS polyacrylamide gel. Protein loading was veri¢ed by using an
antibody speci¢c for the housekeeping gene product b-actin (mouse
monoclonal IgG1k 1:5000). Data from b-actin densitometry analysis of
whole extracts of HuT-78 cells and PBMC from patients 2 and 8 were used
to calculate the respective ratio of modi¢cation in Bcl-2 expression. Results
are expressed as ratio (-fold) of the respective untreated control samples.
Table IV. E¡ects of antioxidant addition and GSH depletion
on As2O3-induced cell death
As2O3 0 mM 0.5 mM 1 mM 2 mM 5 mM
PBMC SS
patient 8
NAC 100.570.1 102.271.7 103.475 99.178.7 110.4744.7
BSO 100.474.7 99.175.7 88.772.5 81.676.3 48.7717.4
HuT-78
cells
NAC 98.170.2 92.8712.8 99.473.2 112.874 110.374.1
BSO 117.871.5 99.973.7 93.871 60.571.2 2.270.1
Results are expressed as the mean percentage of viable cells (annexin/IP),
with the untreated cells taken as a 100% reference, after 24 h of treatment with
increasing concentrations of As2O3, in the presence or not of 10 mM N-acetylcys-
teine (NAC) or 100 mM buthionine sulfoxide (BSO) (mean%7SD, n¼ 3).
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in other CTCL cell lines, and chemical inhibitors of NF-kB have
been shown to promote CTCL death in vitro (Giri and Aggarwal,
1998; Izban et al, 2000). Consequently, it would be warranted to
investigate correlations between NF-kB activity and the CTCL
sensiti-vity to As2O3-induced cell death, and the e¡ects of inhi-
bitors of this pathway on As2O3-induced killing of CTCL cells.
In conclusion, we have found evidence that As2O3 synergizes
with ascorbic acid to induce apoptosis of CTCL cells in vitro.
Furthermore, preliminary results from a phase I/II clinical trial
suggest that monotherapy with As2O3 is able to induce a clinical
response of CTCL skin lesions, thus supporting the relevance in
vivo of data obtained in vitro. Further therapeutic trials in CTCL
patients are now warranted to evaluate the clinical e⁄cacy of
As2O3 in patients with MF/SS, and to determine whether ascor-
bic acid might potentiate in vivo the pro-apoptotic e¡ects of
As2O3 on CTCL cells.
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Figure11. In situ apoptosis detection in skin lesions from patient 9 and patient 6 before and after in vivo treatment with As2O3. Apoptotic cells
were detected in tumor skin lesions by using an in situTUNEL assay (DermaTACS, R&D Systems). Skin biopsies were performed on patient 9 at the site of
a tumor nodule before (A) and at the end (B, B0) of the ¢rst 14 d cycle of As2O3 treatment (magni¢cation: A, B, 100 ; B0, 250 ). Similar experiments were
performed on lesional skin biopsies from patient 6, before (C) and after (D, D0) treatment with As2O3 (magni¢cation: C, D, 250 ; D0, 500 ). Numerous
apoptotic cells, revealed by a dark blue nuclear staining after TUNEL analysis, are detected among the tumoral skin in¢ltrate from patients 9 and 6 after
As2O3 treatment (B, B0, D, D0), whereas only few apoptotic cells are observed prior to therapy (A, C). For patient 6, in situ immunostaining analysis with an
anti-TCRBV11 monoclonal antibody (1:10) allows an evaluation of tumor cells among the skin in¢ltrate, before (E) and after (F) As2O3 infusions. Results
show that in¢ltrating cells belong to the malignant population as shown byTCRVB11 expression and reside in the dermis (immunoperoxidase stain with
hematoxylin counterstain). Magni¢cation: (E), (F) 250 .
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